Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Unrealized Gain (Loss) on Investments

Unrealized Gain (Loss) on Investments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s unrealized gain (loss) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s unrealized gain (loss) on investments?
Iovance Biotherapeutics, Inc. (IOVA) reported unrealized gain (loss) on investments of $85K in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s unrealized gain (loss) on investments changed year-over-year?
Iovance Biotherapeutics, Inc.'s unrealized gain (loss) on investments decreased by 22.7% year-over-year, from $110K to $85K.